ImmunoForge Plans Strategic Partnerships at Bio-Europe Spring 2026 in Portugal ImmunoForge Co., Ltd. aims to establish strategic partnerships at Bio-Europe Spring 2026, showcasing their innovative biopharmaceutical technologies and therapies.

ImmunoForge Plans Strategic Partnerships at Bio-Europe Spring 2026 in Portugal #South_Korea #Seoul #ImmunoForge #PF1801 #LMT15

ImmunoForge Engages with Global Pharma at 2026 J.P. Morgan Healthcare Conference ImmunoForge will hold strategic meetings with pharmaceutical companies during the 2026 J.P. Morgan Healthcare Conference to advance its innovative treatments.

ImmunoForge Engages with Global Pharma at 2026 J.P. Morgan Healthcare Conference #South_Korea #Seoul #ImmunoForge #PF1801 #PF1804

FDA and MFDS Approve ImmunoForge’s Leading Drugs for DMD and CML, Accelerating Clinical Trials ImmunoForge, a pioneering biotech company, is making significant strides in the treatment of serious medical conditions with the recent approval of two Investigational New Drug (IND) applications by r...

www.linkedin.com/pulse/fda-mf...

FDA and MFDS Approve ImmunoForge’s Leading Drugs for DMD and CML, Accelerating Clinical Trials

kstrategyand.com/pharma-news

#ImmunoForge #FDAApproval #Pemziviptadil #DMDCardiomyopathy #PharmaceuticalNews #FDA #MFDS #Humanteconomy #Humantec #KStrategyand

Weekly Roundup - PHARMA - 20 January 2025 🔊Autolus Therapeutics Secures FDA Approval for Aucatzyl Cell Therapy in Relapsed B-Cell Leukemia Autolus Therapeutics is launching Aucatzyl commercially in the U.S.

🚀 Weekly Roundup - PHARMA - 20 January 2025

www.linkedin.com/pulse/weekly...

kstrategyand.com/pharma-news

#AutolusTherapeutics #BannerLifeSciences #Bafiertam #Pfizer #Sasanlimab #TyraBiosciences #ImmunoForge #Pemziviptadil #PharmaNews #ClinicalTrials #Humanteconomy #Humantec #KStrategyand

ImmunoForge Receives FDA IND Approval for Phase 2 Clinical Trial of ‘Pemziviptadil’ for DMD Cardiomyopathy The U.S. Food and Drug Administration (FDA) has approved ImmunoForge's Phase 2 clinical trial IND for "Pemziviptadil (development code name PF1804)," a treatment for DMD (Duchenne Muscular Dystrophy) cardiomyopathy. A medication for DMD cardiomyopathy, pemziviptadil is used once a week and is based on ImmunForge’s ELP Platform (Elastin Like Polypeptide Platform), a long-acting pharmacological platform. In order to improve cardiac function, pemziviptadil, a vasoactive intestinal peptide (VIP), preferentially works on the vasoactive intestinal peptide receptor 2 (VPAC2) to promote heart contraction and relaxation.

ImmunoForge Receives FDA IND Approval for Phase 2 Clinical Trial of ‘Pemziviptadil’ for DMD Cardiomyopathy

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennesmusculardystrophy #musculardystrophy #gene #dna #ImmunoForge #Pemziviptadil #pf1804

ImmunoForge Achieves Milestone with IND Approval for Pemziviptadil and KF1601 in US and Korea ImmunoForge has secured IND approvals for Phase 2 trial of Pemziviptadil for DMD cardiomyopathy and Phase 1 trial for KF1601 targeting leukemia, marking critical progress.

ImmunoForge Achieves Milestone with IND Approval for Pemziviptadil and KF1601 in US and Korea #South_Korea #Seoul #ImmunoForge #Pemziviptadil #KF1601